Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.
Bazan V, Agnese V, Corsale S, Calò V, Valerio MR, Latteri MA, Vieni S, Grassi N, Cicero G, Dardanoni G, Tomasino RM, Colucci G, Gebbia N, Russo A; Gruppo Oncologico dell'Italia Meridionale (GOIM). Bazan V, et al. Among authors: cicero g. Ann Oncol. 2005 May;16 Suppl 4:iv50-55. doi: 10.1093/annonc/mdi908. Ann Oncol. 2005. PMID: 15923430 Free article.
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma.
Valerio MR, Tagliaferri P, Raspagliesi F, Fulfaro F, Badalamenti G, Arcara C, Cicero G, Russo A, Venuta S, Guarneri G, Gebbia N. Valerio MR, et al. Among authors: cicero g. Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:79-85. doi: 10.1111/j.1525-1438.2006.00324.x. Int J Gynecol Cancer. 2006. PMID: 16515572 Clinical Trial.
Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.
Agnese V, Corsale S, Calò V, Augello C, Bruno L, Calcara D, Crosta A, Rodolico V, Rinaldi G, Cicero G, Latteri F, Agrusa A, Morello V, Adamo V, Altavilla G, Di Fede G, Fiorentino E, Grassi N, Latteri MA, Valerio MR, Tomasino RM, Colucci G, Bazan V, Russo A; Gruppo Oncologico dell'Italia Meridionale. Agnese V, et al. Among authors: cicero g. Ann Oncol. 2006 Jun;17 Suppl 7:vii137-41. doi: 10.1093/annonc/mdl967. Ann Oncol. 2006. PMID: 16760277 Free article.
Detection and quantification of mammaglobin in the blood of breast cancer patients: can it be useful as a potential clinical marker? Preliminary results of a GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.
Gargano G, Agnese V, Calò V, Corsale S, Augello C, Bruno L, La Paglia L, Gullo A, Ottini L, Russo A, Fulfaro F, Rinaldi G, Crosta A, Cicero G, Majorana O, Palmeri L, Cipolla C, Agrusa A, Gulotta G, Morello V, Di Fede G, Adamo V, Colucci G, Tomasino RM, Valerio MR, Bazan V, Russo A; Gruppo Oncologico dell'Italia Meridionale. Gargano G, et al. Among authors: cicero g. Ann Oncol. 2006 Jun;17 Suppl 7:vii41-5. doi: 10.1093/annonc/mdl948. Ann Oncol. 2006. PMID: 16760290 Free article.
Bortezomib: a new pro-apoptotic agent in cancer treatment.
Russo A, Bronte G, Fulfaro F, Cicero G, Adamo V, Gebbia N, Rizzo S. Russo A, et al. Among authors: cicero g. Curr Cancer Drug Targets. 2010 Feb;10(1):55-67. doi: 10.2174/156800910790980250. Curr Cancer Drug Targets. 2010. PMID: 20088794
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G. Santini D, et al. Among authors: cicero g. Ann Oncol. 2012 Sep;23(9):2313-2318. doi: 10.1093/annonc/mdr623. Epub 2012 Mar 5. Ann Oncol. 2012. PMID: 22396447 Free article. Clinical Trial.
216 results